There is no approved HIV vaccine available today. Despite more than four decades of research and billions of dollars in funding, HIV has proven to be one of the most difficult targets in vaccine science. Several major clinical trials in recent years have failed to show meaningful protection, though a newer generation of experimental approaches is now in early-stage testing with genuinely promising early signals.
Why HIV Is So Hard to Vaccinate Against
Most successful vaccines work by teaching the immune system to recognize a specific protein on a virus’s surface. HIV makes this extraordinarily difficult for several reasons, all rooted in the virus’s biology.
The outer surface of HIV is covered by a protein called the envelope protein, and this protein is coated in sugar molecules so dense they account for roughly half its total mass. With about 95 sugar attachment points on each protein, this “glycan shield” acts like a molecular disguise. The immune system’s antibodies approach the virus and effectively see a blurry cloud of sugars rather than the vulnerable protein underneath. Antibodies that do manage to target the surface tend to focus on the few patches where sugars are sparse, but those patches vary widely between HIV strains.
HIV also mutates at an exceptional rate. The virus copies its genetic material sloppily, generating enormous diversity even within a single infected person. A vaccine that trains the immune system to recognize one version of the virus may be useless against another. There are dozens of major subtypes circulating globally, and countless variants within each subtype. This is fundamentally different from a virus like measles, which barely changes from decade to decade.
Finally, HIV attacks the very immune cells (called CD4 cells) that coordinate the body’s defense against infection. The virus essentially targets the system designed to fight it.
Two Types of HIV Vaccines Under Study
Researchers are pursuing two distinct goals. A preventive HIV vaccine would be given to people who don’t have HIV, training their immune systems to block the virus before infection takes hold. This is what most people picture when they think of a vaccine.
A therapeutic HIV vaccine takes a different approach entirely. It’s designed for people already living with HIV, with the goal of strengthening their immune response enough to control the virus without daily antiretroviral medication. Neither type is available yet, but both are active areas of research.
Major Trials That Have Failed
Understanding the current landscape means understanding what hasn’t worked. The most recent high-profile failures involved a strategy that used a mosaic vaccine, a design that stitched together pieces of multiple HIV strains to try to provide broad protection.
The Imbokodo trial tested this approach in women across southern Africa. It found a vaccine efficacy of just 14%, a result so low it was statistically indistinguishable from zero. The trial was stopped early because there was no meaningful protection. A parallel trial called Mosaico, which tested a similar regimen in men who have sex with men and transgender individuals, was also halted for the same reason.
More recently, the PrEPVacc trial stopped vaccinations in November 2023 after independent monitors determined the vaccines being tested had little or no chance of demonstrating efficacy. These repeated setbacks illustrate a pattern: traditional vaccine strategies that work for other viruses have consistently fallen short against HIV.
A New Strategy: Training Rare Immune Cells
The most scientifically exciting work right now takes a fundamentally different approach. Instead of trying to directly generate protective antibodies, researchers are attempting something that had previously only been achieved in genetically engineered mice: guiding the immune system through a multi-step process to produce a special class of antibodies called broadly neutralizing antibodies.
These antibodies are rare but powerful. They can block many different strains of HIV at once by targeting the few conserved spots on the virus that don’t change much between variants. Some latch onto the exact site where HIV attaches to human cells. Others wedge into gaps between the sugar molecules of the glycan shield. In nature, only a small fraction of people with HIV ever develop these antibodies, and it typically takes years of infection for them to appear. The goal of this new vaccine strategy is to jumpstart that process artificially.
The approach is called germline targeting. Everyone carries a tiny population of immature immune cells that have the potential, with the right series of nudges, to mature into cells that produce broadly neutralizing antibodies. The first step is finding a molecule that can activate those rare precursor cells. A candidate called eOD-GT8 60mer, developed by teams at IAVI and Scripps Research, was designed to do exactly that.
In a Phase 1 trial called IAVI G001, 48 healthy volunteers received either the vaccine or a placebo. The results were striking: the vaccine successfully activated the target precursor cells at frequencies high enough to be considered promising for the next step, a booster shot designed to push those cells further along their maturation pathway. Peter Kwong of the NIH’s Vaccine Research Center noted that this kind of precise control over early antibody development had previously only been seen in genetically modified mice, and that the Phase 1 results suggested it could also be achieved in humans.
This is still very early. Activating the right precursor cells is only step one of what will likely be a multi-shot regimen, with each dose guiding the immune response closer to producing mature broadly neutralizing antibodies. But it represents a genuine proof of concept that had eluded researchers for years.
mRNA Technology Enters HIV Research
The mRNA platform that powered COVID-19 vaccines is now being applied to HIV. IAVI and Moderna have partnered to deliver the same germline-targeting molecule (eOD-GT8 60mer) using mRNA instead of traditional protein-based delivery. The potential advantage is faster manufacturing and the ability to fine-tune the immune response.
A Phase 1 trial in U.S. populations is evaluating the mRNA version, and a companion trial called IAVI G003 launched in Africa to test whether the approach triggers similar immune responses across different populations. The African trial enrolled 18 healthy, HIV-negative adults who each received two doses. The mRNA construct contains only a portion of the viral genetic sequence and cannot cause HIV infection.
These trials are still in their earliest stages, designed to test safety and immune responses rather than real-world protection. If the mRNA delivery proves effective at priming the right immune cells, the next challenge will be designing the sequence of booster shots needed to drive those cells toward producing broadly neutralizing antibodies.
What a Realistic Timeline Looks Like
Even with the promising germline-targeting results, an effective HIV vaccine remains years away at minimum. The multi-step approach means researchers need to develop and test not just one vaccine, but a carefully sequenced series of shots, each building on the immune response generated by the last. Every step requires its own clinical trials.
The history of HIV vaccine research is a long record of promising ideas that didn’t translate into protection in large trials. What makes the current moment different is that researchers have, for the first time, demonstrated they can deliberately guide the human immune system toward producing the kind of antibodies known to neutralize HIV broadly. Whether that initial success can be built into full protection is the central question for the next decade of research.